Best Practice and Research. Clinical Haematology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Current and Potential Applications of Positron Emission Tomography for Multiple Myeloma and Plasma Cell Disorders
Publication date: Available online 17 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Gary A. Ulaner, C. Ola LandgrenAbstractFluorine-18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET) allows evaluation of elevated glucose metabolism in malignancies. There has been increasing interest in FDG PET/CT for plasma cell disorders since the International Myeloma Working Group outlined multiple applications of this imaging modality, including distinguishing smoldering myeloma from active multiple myeloma, confirmation of solitary plasmacytoma, and multiple indications in patients with ...
Source: Best Practice and Research Clinical Haematology - January 18, 2020 Category: Hematology Source Type: research
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Benjamin Diamond, Kylee Maclachlan, David J. Chung, Alexander Lesokhin, C. Ola LandgrenAbstractWith ten years of follow-up since the advent of the modern paradigm of combination induction therapy, consolidative autologous stem-cell transplant, and lenalidomide maintenance, median survival for multiple myeloma has increased to almost 50% at 10 years. Given this outlook, the overarching goal of maintenance therapy is to spare patients from the toxicities of aggressive or otherwise intrusive therapies while ideall...
Source: Best Practice and Research Clinical Haematology - January 15, 2020 Category: Hematology Source Type: research
Tracking myeloma tumor DNA in peripheral blood
Publication date: Available online 14 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Johannes M. Waldschmidt, Tushara Vijaykumar, Birgit Knoechel, Jens G. LohrAbstractOver the past years, the emergence of liquid biopsy technologies has dramatically expanded our ability to assess multiple myeloma without the need for invasive sampling. Interrogation of cell-free DNA from the peripheral blood recapitulates the mutational landscape at excellent concordance with matching bone marrow aspirates. It can quantify disease burden and identify previously undetected resistance mechanisms which may inform c...
Source: Best Practice and Research Clinical Haematology - January 15, 2020 Category: Hematology Source Type: research
CAR T and CAR NK cells in multiple myeloma: expanding the targets
Publication date: Available online 13 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Urvi A. Shah, Sham MailankodyAbstractMultiple myeloma (MM) is a haematologic malignancy with significant improvements in the overall survival over the last decade. However, patients still relapse and die due to a lack of treatment options. Ultimately, novel therapies with the potential for long term remissions are needed for patients with advanced MM. Research efforts for such immune therapies were not successful until recently when the first immunotherapies for MM were approved in 2015 and many more are under ...
Source: Best Practice and Research Clinical Haematology - January 14, 2020 Category: Hematology Source Type: research
Monoclonal Antibodies in Multiple Myeloma: Current and Emerging Targets and Mechanisms of Action
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Kitsada Wudhikarn, Beatriz Wills, Alexander M. LesokhinAbstractThe recent development of monoclonal antibodies (mAbs) has revolutionized the treatment armamentarium for multiple myeloma. The success of daratumumab and elotuzumab in relapsed/refractory patients, has generated tremendous enthusiasm for mAbs in this disease. Combination treatment with other anti-MM treatment modalities and clinical evaluation in newly diagnosed patients are expected to fundamentally change the natural history of the disease. Advan...
Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research
Second malignancies in multiple myeloma; emerging patterns and future directions
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Kylee Maclachlan, Benjamin Diamond, Francesco Maura, Jens Hillengass, Ingemar Turesson, C. Ola Landgren, Dickran KazandjianAbstractThe changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of ...
Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research
Tracking of low disease burden in multiple myeloma: using mass spectrometry assays in peripheral blood
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Jessica R. Chapman, Katie L. ThorenAbstractEfforts over the last 5 years have demonstrated that it is technically feasible to detect low levels of monoclonal proteins in peripheral blood using mass spectrometry. These methods are based on the fact that an M-protein has a specific amino acid sequence, and therefore, a specific mass. This mass can be tracked over time and can serve as a surrogate marker of the presence of clonal plasma cells. This review describes the use of mass spectrometry to detect M-proteins...
Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research
“Maintenance therapy and need for cessation studies in multiple myeloma: focus on the future”
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Benjamin Diamond, Kylee Maclachlan, David J. Chung, Alexander Lesokhin, C. Ola LandgrenAbstractWith ten years of follow-up since the advent of the modern paradigm of combination induction therapy, consolidative autologous stem-cell transplant, and lenalidomide maintenance, median survival for multiple myeloma has increased to almost 50% at 10 years. Given this outlook, the overarching goal of maintenance therapy is to spare patients from the toxicities of aggressive or otherwise intrusive therapies while ideall...
Source: Best Practice and Research Clinical Haematology - January 12, 2020 Category: Hematology Source Type: research
Reconstructing the evolutionary history of multiple myeloma
Publication date: Available online 11 January 2020Source: Best Practice & Research Clinical HaematologyAuthor(s): Francesco Maura, Even H. Rustad, Eileen M. Boyle, Gareth J. MorganABSTRACTMultiple myeloma is the second most common lymphoproliferative disorders, characterized by aberrant expansion of monoclonal plasma cells. In the last years, thanks to novel next generation sequencing technologies, multiple myeloma has emerged as one of the most complex hematological cancers, shaped over time by the activity of multiple mutational processes and by the acquisition of key driver events. In this review, we describe how whole ...
Source: Best Practice and Research Clinical Haematology - January 11, 2020 Category: Hematology Source Type: research
Contemporary treatment approaches to CMML – is allogeneic HCT the only cure?
Publication date: Available online 30 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Marie Robin, Raphael ItzyksonAbstractChronic Myelomonocytic Leukemias are frequently diagnosed in older adults. Their prognosis is heterogeneous, but several prognostic factors can identify patients with an expected survival of a few years only, including among younger patients eligible for allogeneic stem cell transplantation.Based on the retrospective data available, we discuss how to identify CMML patients for whom curative therapy must be envisaged. We emphasize that, although transplantation remains the o...
Source: Best Practice and Research Clinical Haematology - December 30, 2019 Category: Hematology Source Type: research
Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?
Publication date: Available online 26 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): V.F.I. Sangiorgio, A. Orazi, D.A. ArberABSTRACTThe term myelodysplastic/myeloproliferative neoplasm (MDS/MPN) refers to a group of clonal hematopoietic neoplasms with overlapping clinical, morphologic and genetic myelodysplastic and myeloproliferative features observed at the time of first presentation. Impaired hematopoiesis morphologically associated with evidence of myelodysplasia manifests clinically with cytopenia/s. Simultaneously, myeloproliferation is seen within the bone marrow and leads to cytosis in...
Source: Best Practice and Research Clinical Haematology - December 27, 2019 Category: Hematology Source Type: research
Atypical CML- the role of morphology and precision genomics
Publication date: Available online 6 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Terra LashoAbstractAtypical chronic myeloid leukemia is an esoteric myeloid malignancy with features of both myeloproliferative and myelodysplastic syndromes. This disease is characterized primarily by morphologic-based criteria, and has clinical and molecular features overlapping with other myeloid malignancies. No one molecular abnormality is specific, and multiple mutations are often present in various combinations, due to the malignant multi-step clonal evolution of myeloid malignancies. In this review, we ...
Source: Best Practice and Research Clinical Haematology - December 19, 2019 Category: Hematology Source Type: research
Autoimmune disease in CMML-the chicken or the egg?
Publication date: Available online 17 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Alexander J. Ambinder, John Miller, Amy E. DeZernABSTRACTChronic myelomonocytic leukemia (CMML) is a clonal disorder that is associated with a wide range of systemic inflammatory and autoimmune diseases (SIADs). Approximately 20% of patients with CMML will have an associated SIAD and recognizing this association is critical to the evaluation, prognostication and management of patients with CMML. In this paper, we review the evidence supporting a causative link between these two entities as well as the directio...
Source: Best Practice and Research Clinical Haematology - December 18, 2019 Category: Hematology Source Type: research
Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management
Publication date: Available online 15 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Peter ValentAbstractChronic myelomonocytic leukemia (CMML) is defined by myelodysplasia, pathologic accumulation of monocytes and a substantial risk to transform to secondary acute myeloid leukemia (sAML). In recent years, minimal diagnostic criteria for classical CMML and CMML-variants were proposed. Moreover, potential pre-stages of CMML and interface conditions have been postulated. Oligomonocytic CMML is a condition where the absolute peripheral blood monocyte count does not reach a diagnostic level but al...
Source: Best Practice and Research Clinical Haematology - December 15, 2019 Category: Hematology Source Type: research
Moving towards a uniform risk stratification system in CMML - how far are we?
Publication date: Available online 6 December 2019Source: Best Practice & Research Clinical HaematologyAuthor(s): Onyee Chan, Eric PadronAbstractMany prognostic scoring systems have been developed for chronic myelomonocytic leukemia (CMML). Although these efforts have been informative, no single model has been considered the consensus for CMML prognostication and all models are only moderately prognostic. CMML clinical models utilize mainly hematology and morphology parameters to estimate risk. A better understanding of cytogenetics and the genomic landscape of CMML have resulted in integrated risk models such as CMML Prog...
Source: Best Practice and Research Clinical Haematology - December 7, 2019 Category: Hematology Source Type: research
